Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arrowhead Pharmaceuticals (ARWR) FCF Margin (2016 - 2025)

Arrowhead Pharmaceuticals' FCF Margin history spans 16 years, with the latest figure at 5.05% for Q4 2025.

  • For Q4 2025, FCF Margin rose 615657.0% year-over-year to 5.05%; the TTM value through Dec 2025 reached 29.7%, up 1969830.0%, while the annual FY2025 figure was 18.91%, 1317174.0% up from the prior year.
  • FCF Margin reached 5.05% in Q4 2025 per ARWR's latest filing, roughly flat from 5.07% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 782.38% in Q1 2021 to a low of 6151.52% in Q4 2024.
  • Average FCF Margin over 5 years is 703.21%, with a median of 182.95% recorded in 2022.
  • Peak YoY movement for FCF Margin: tumbled -345349bps in 2023, then surged 615657bps in 2025.
  • A 5-year view of FCF Margin shows it stood at 244.49% in 2021, then rose by 25bps to 182.95% in 2022, then tumbled by -1888bps to 3636.44% in 2023, then tumbled by -69bps to 6151.52% in 2024, then soared by 100bps to 5.05% in 2025.
  • Per Business Quant, the three most recent readings for ARWR's FCF Margin are 5.05% (Q4 2025), 5.07% (Q3 2025), and 610.58% (Q2 2025).